Mark J. O'Connor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mark J. O'Connor has a total of 436 co-authors. Here are the top co-authors by number of shared publications:
- Susan E. Critchlow
Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
90 shared publications - Stephen E. Fawell
Oncology R&D, AstraZeneca, Boston, Massachusetts
79 shared publications - Krishna C. Bulusu
Oncology Data Science, AstraZeneca, Cambridge, UK
65 shared publications - James Hall
Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre
64 shared publications - Violeta Serra
Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology, Barcelona, Spain
63 shared publications - Judith Balmaña
Hereditary Cancer Genetics Unit, Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
62 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Springer Nature in npj Breast Cancer
Understanding mechanisms of PARP inhibitor resistance
- 30 September 2026
- Published by Springer Nature in npj Breast Cancer
Open AccessUnderstanding mechanisms of PARP inhibitor resistance
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
MDA single cells annotation in cell types
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
MDA single cells annotation in cell types
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Natural Killer (NK) cells depletion in vivo
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Natural Killer (NK) cells depletion in vivo
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Coupled single cell RNA and TCR sequencing reveals hyperexpanded TCR clonotypes expressing tumor related signatures
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Coupled single cell RNA and TCR sequencing reveals hyperexpanded TCR clonotypes expressing tumor related signatures
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S12 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
PARPi affects the peripheral immune composition in patients
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
PARPi affects the peripheral immune composition in patients
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Interferon responses up-regulation in MDA tumor microenvironment
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Interferon responses up-regulation in MDA tumor microenvironment
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
STING-related biomarkers in BC PDXs
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
STING-related biomarkers in BC PDXs
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Table S4 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Table S4 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Bulk RNA sequencing of PDX230OR8 tumors
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Bulk RNA sequencing of PDX230OR8 tumors
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Same HRR functionality, PARP enzymatic inhibition and DNA damage in different mouse strains
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Same HRR functionality, PARP enzymatic inhibition and DNA damage in different mouse strains